Pharmaceuticals

mRNA Therapeutics Industry Poised for Rapid Growth, Forecast to Touch $42.32 Billion by 2030 at 3.3% CAGR

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the mrna therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the mRNA Therapeutics Market reach by 2030 starting from 2026 levels?

The mrna therapeutics market has observed consistent expansion in recent years. Its size is expected to increase from $35.9 billion in 2025 to $37.18 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.6%. This historical development can be attributed to the significant achievements of mrna vaccines in infectious diseases, progress in nucleic acid delivery technologies, an enhanced understanding of gene expression regulation, early research confirmation of mrna-based protein synthesis, and substantial public funding for mrna research platforms.

The mrna therapeutics market size is projected for consistent expansion in the coming years, with expectations to reach $42.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 3.3%. This anticipated growth can be primarily linked to several factors, including the increasing demand for targeted and personalized therapies, the broadening application of mrna in oncology and rare diseases, rising biopharmaceutical investment in mrna pipelines, an increasing number of mrna drugs progressing into clinical trials, and strategic partnerships between biotech firms and research organizations. Major developments anticipated in this forecast period include the expansion of mrna therapeutics beyond vaccines, a growing emphasis on protein replacement therapies utilizing mrna, a burgeoning clinical pipeline for non-vaccine mrna drugs, heightened investment in lipid nanoparticle delivery systems, and the acceleration of end-to-end mrna manufacturing capabilities.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17205&type=smp

Which Drivers Are Influencing Long-Term Growth In The mRNA Therapeutics Market?

The expanding occurrence of chronic and infectious illnesses is anticipated to drive the future expansion of the mRNA therapeutics market. These diseases are defined as conditions that endure over prolonged durations and can be transmitted among people, encompassing ailments like tuberculosis, HIV/AIDS, and hepatitis. This surge in diseases stems from elements such as heightened worldwide travel and deficiencies in healthcare systems, which foster higher rates of transmission and impede efficient disease control. mRNA therapeutics aid in enhancing disease management by quickly allowing the body to generate proteins that boost immune responses, thereby accelerating the creation of specific vaccines and therapies. For example, data from March 2024, supplied by the Centers for Disease Control and Prevention, a US-based government agency, indicated a rise in tuberculosis cases from 8,320 in 2022 to 9,615 in 2023, marking an increment of 1,295 cases. Consequently, the growing frequency of long-lasting and communicable diseases is fueling the expansion of the mRNA therapeutics market.

How Is The mRNA Therapeutics Market Divided Into Segments?

The mrna therapeutics market covered in this report is segmented –

1) By Product: Vaccines, Drugs

2) By Application: Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications

3) By End Use: Hospitals And Clinics, Research Organizations, Other End Uses

Subsegments:

1) By Vaccines: Infectious Disease Vaccines, Cancer Vaccines, Other Therapeutic Vaccines

2) By Drugs: Oncology Drugs, Cardiovascular Drugs, Autoimmune Disease Drugs, Other mRNA-Based Drugs

Which Trends Are Shaping Activity Within The mRNA Therapeutics Market?

Leading firms active within the mRNA therapeutics market are concentrating on creating cutting-edge solutions, including personalized neoantigen vaccines, with the goal of bolstering immune response and bettering survival rates for cancer patients. These personalized neoantigen vaccines represent cancer treatments tailored individually, leveraging distinct tumor-specific genetic alterations to prompt the immune system to identify and eliminate malignant cells. As an example, in July 2023, Merck & Co., Inc., a US-based research-intensive biopharmaceutical company, collaborated with Moderna Therapeutics, Inc., a US-based biotechnology company, to commence a Phase 3 randomized clinical trial (V940-001). This trial aims to assess mRNA-4157 (V940) when combined with KEYTRUDA® (pembrolizumab) for use as an adjuvant therapy in individuals suffering from resected high-risk (Stage IIB-IV) melanoma. This investigation follows promising outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which demonstrated a significant advantage of the combined treatment compared to KEYTRUDA by itself in decreasing the likelihood of recurrence and distant metastasis. The Phase 3 trial seeks to validate these observations by measuring relapse-free survival as its primary endpoint and distant metastasis-free survival as its secondary endpoint.

Which Key Players Are Driving Competition In The mRNA Therapeutics Market?

Major companies operating in the mrna therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Which Region Is Projected To Lead The mRNA Therapeutics Market During The Forecast Period?

North America was the largest region in the mRNA therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized mRNA Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17205&type=smp

Browse Through More Reports Similar to the Global mRNA Therapeutics Market 2026, By The Business Research Company

Mrna Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report

Ribose Nucleic Acid Rna Based Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

Rna Targeting Small Molecules Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795